Giannis Mountzios
YOU?
Author Swipe
View article: Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity Open
View article: Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry Open
Background With nearly one-third of patients with advanced non-small cell lung cancer (NSCLC) and PD-L1 Tumor Proportion Score≥50% surviving beyond 5 years following first-line pembrolizumab, long-term outcomes challenge traditional paradi…
View article: Beyond Programmed Death-Ligand 1: Gut Microbiome Composition as a Biomarker For First-Line Chemoimmunotherapy in Advanced NSCLC
Beyond Programmed Death-Ligand 1: Gut Microbiome Composition as a Biomarker For First-Line Chemoimmunotherapy in Advanced NSCLC Open
View article: Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer Open
Molecular determinants of KRAS(G12C)inhibitor efficacy in KRASG12C-mutated non-small-cell lung cancer (NSCLC) remain poorly characterized. Here we report one of the largest integrated analyses to date of sotorasib clinical effic…
View article: Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary
Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary Open
What is this summary about?The CodeBreaK 200 clinical study included patients with a type of lung cancer called non–small-cell lung cancer that has spread outside the lung (advanced) and had a particular change (mutation) in the KRAS gene.…
View article: Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target
Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target Open
View article: Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry Open
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-…
View article: De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence? Open
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, with ICBs administered at flat doses reg…
View article: 534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry Open
View article: Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
View article: Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain me…
View article: Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
View article: Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NG…
View article: Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
View article: Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NG…
View article: Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors …
View article: Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort A
View article: Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A and B.
View article: Supplementary Table S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Multivariable analysis - progression-free survival
View article: Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort A
View article: Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
View article: Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
View article: Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Multivariable analysis - overall survival
View article: Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Multivariable analysis - overall survival
View article: Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
View article: Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
View article: Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort B
View article: Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort B
View article: Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A and B.
View article: Supplementary Figure S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to TP53 co-mutation status in A) overall cohort, B) cohort A, and C) cohort B.